Loading clinical trials...
Loading clinical trials...
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model
Conditions
Interventions
BTA-C585 oral capsule
Matching placebo capsules
Locations
1
United Kingdom
Biota Investigational Site
London, United Kingdom
Start Date
March 1, 2016
Primary Completion Date
December 1, 2016
Completion Date
December 1, 2016
Last Updated
May 30, 2018
Lead Sponsor
Biota Pharma Europe Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions